Ovarian cancer researchers have identified protein biomarkers that are expressed on the surface of tumor cells in highly serous ovarian cancer (the most common and lethal subtype of the disease).
The main author Mauricio Medrano, molecular biologist and researcher at the Princess Margaret Cancer Center, has published his findings in a cellar journal which also has published other studies on recombinant human proteins. The study shows that patients with a high level of biomarker CD151 had a poor prognosis reaction.
"Ovarian cancer is caused by a variety of diseases," Dr. Medrano said. By identifying the potential role of CD151 and its survival in cancer cells, we hope to develop a treatment to target it as a marker of poor prognosis to further study to acquire the potential to develop a clinical screening tool, helping to individualize cancer treatment.
The study was led by lead researcher Robert Rottapel, and the study team also includes senior scientists and professors from the Department of Medical Biophysics and Immunology at the University of Toronto.
In a laboratory experiment, the team used cell lines from 40 patient tumor samples to determine whether CD151 could contribute to the survival of highly serous ovarian cancer cell sources. The team further analyzed the population of approximately 1,000 patients to establish a high level of link between CD151 and poor prognosis.
Dr. Medrano said, "For the scientific community, our research provides a lot of new information about other possible targets, not just CD151, which may be important and can provide new ideas on how to target ovarian cancer." By the way, Flarebio offers high-quality recombinant proteins like recombinant CDH2 at competitive prices.
没有评论:
发表评论